3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Not yet recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Conditions
Colorectal Neoplasms
24
Neoplasms
12
Colonic Neoplasms
12
Breast Neoplasms
12
Prostatic Neoplasms
9
Polycythemia Vera
9
Venous Thromboembolism
8
Multiple Myeloma
8
Recurrence
5
Rectal Neoplasms
5
Carcinoma, Non-Small-Cell Lung
5
Thrombocythemia, Essential
4
Ovarian Neoplasms
4
Neoplasms, Plasma Cell
4
Neoplasm Metastasis
4
Myeloproliferative Disorders
4
Barrett Esophagus
4
Precancerous Conditions
3
Melanoma
3
Esophageal Neoplasms
3
Adenomatous Polyps
3
Adenoma
3
Tobacco Use Disorder
2
Thrombosis
2
Thromboembolism
2
Smoking Cessation
2
Sarcoma
2
Primary Myelofibrosis
2
Neoplastic Cells, Circulating
2
Neoplasms by Site
2
Interventions
Cisplatin
55
Carboplatin
50
pembrolizumab
42
Paclitaxel
42
Gemcitabine
28
Pemetrexed
23
Radiotherapy
21
Magnetic Resonance Spectroscopy
20
Radiotherapy, Intensity-Modulated
18
Docetaxel
17
Cetuximab
17
Specimen Handling
16
Nivolumab
16
Fluorouracil
16
Cyclophosphamide
14
durvalumab
13
Bevacizumab
12
Radiation
11
130-nm albumin-bound paclitaxel
11
Sorafenib
10
Platinum
10
1,2-diaminocyclohexaneplatinum II citrate
10
osimertinib
9
Sunitinib
8
Oxaliplatin
8
Irinotecan
8
Ipilimumab
8
Everolimus
8
Drug Therapy
8
Capecitabine
8
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Interventional
×
Carcinoma
×
Aspirin
×
Clear all
NCT07529262
2026-04-14
AspiRe HCC
Curtin University
Phase 3
Not yet recruiting
890 enrolled